Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study
Journal article
Jackson S. et al, (2024), The Lancet Microbe, 5, 655 - 668
Randomized, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.
Journal article
Audran R. et al, (2024), J Infect
Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patients.
Journal article
Ongarj J. et al, (2024), Tuberculosis (Edinburgh, Scotland), 148
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial
Journal article
Satti I. et al, (2024), The Lancet Infectious Diseases
Deficiency of factor-inhibiting HIF creates a tumor-promoting immune microenvironment.
Journal article
Ma J. et al, (2024), Proceedings of the National Academy of Sciences of the United States of America, 121
Revaccination with BCG: does it work?
Journal article
McShane H., (2024), The Lancet. Infectious diseases
Improving TB vaccine trial efficiency: A tough nut to crack.
Journal article
Mcshane H., (2023), The Journal of infectious diseases
Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges.
Journal article
Morrison H. et al, (2023), Frontiers in immunology, 14
Practical considerations for a TB controlled human infection model (TB-CHIM); the case for TB-CHIM in Africa, a systematic review of the literature and report of 2 workshop discussions in UK and Malawi.
Journal article
Gordon SB. et al, (2023), Wellcome Open Res, 8
Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants
Journal article
Satti I. et al, (2022), Nature Communications, 13
Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop.
Journal article
Williams E. et al, (2022), Vaccine, 40, 3484 - 3489
Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study.
Journal article
Wilkie M. et al, (2022), Scientific reports, 12
Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?
Journal article
Dockrell HM. and McShane H., (2022), EBioMedicine, 79
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.
Journal article
Killingley B. et al, (2022), Nat Med
Challenges in Developing a Controlled Human Tuberculosis Challenge Model.
Journal article
Jackson S. and McShane H., (2022), Curr Top Microbiol Immunol
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial
Journal article
Fisher BA. et al, (2022), The Lancet Respiratory Medicine, 10, 255 - 266
Rapid research response to the COVID-19 pandemic: perspectives from a National Institute for Health Biomedical Research Centre.
Journal article
Henderson LR. et al, (2022), Health research policy and systems, 20
“It seems impossible that it’s been made so quickly”: a qualitative investigation of concerns about the speed of COVID-19 vaccine development and how these may be overcome
Journal article
Brown P. et al, (2022), Human Vaccines & Immunotherapeutics, 1 - 8
A large National Institute for Health Research (NIHR) Biomedical Research Centre facilitates impactful cross-disciplinary and collaborative translational research publications and research collaboration networks: a bibliometric evaluation study
Journal article
Kiparoglou V. et al, (2021), Journal of Translational Medicine, 19
Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease.
Journal article
Burel JG. et al, (2021), Tuberculosis (Edinburgh, Scotland), 131